GlassScriptPhysician profile
Kate Moya
NPI 1952733677
$3,973.56
in general payments reported to CMS, 2019-2025
21 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $158 · 2023: $745 · 2024: $1,045 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.51 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $720.92 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $422.73 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $325.83 | 2023-2025 | |
| Ardelyx, INC. | $283.60 | 2022-2025 | Ibsrela |
| Evoke Pharma, INC. | $235.61 | 2024-2025 | |
| Janssen Biotech, INC. | $235.07 | 2021-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $194.81 | 2025 | Sucraid |
| Genzyme Corporation | $165.32 | 2025 | |
| Phathom Pharmaceuticals, INC. | $128.48 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $81.54 | 2023-2024 | Sutab, Suflave |
| Pfizer INC. | $72.75 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $52.09 | 2024-2025 | Bylvay, Iqirvo |
| Redhill Biopharma INC. | $49.26 | 2021-2024 | Talicia |
| Celltrion USA INC. | $45.75 | 2025 | Vegzelma |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $32.11 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $26.06 | 2025 | Dupixent |
| Celgene Corporation | $24.30 | 2023 | Zeposia |
| Daiichi Sankyo INC. | $21.05 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $20.48 | 2024 | Dificid |
| Vivus LLC | $19.29 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Moya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.